SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as the community eagerly anticipates pivotal Phase 3 data for its GPS cancer immunotherapy, with CEO comments on potential curative outcomes driving strong speculation of a massive short squeeze. Investors are actively dismissing bearish takes, instead focusing on shattered technical resistance and accumulation signals that point to a major market revaluation or buyout.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as its recent earnings and management commentary highlight balance sheet stability, positive free cash flow, and international growth, leading to strong community discussion about its significant undervaluation and AI leadership within the expanding telehealth sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to investor concerns over a recently announced convertible senior notes offering, which has sparked questions about potential dilution and management's confidence despite a strong cash position. This comes amidst ongoing community speculation regarding a potential buyout and anticipation for accelerating sales of its gene therapy, Casgevy, and future pipeline updates.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is heavily discussed ahead of its earnings report, with investor sentiment torn between the potential of its AI infrastructure and cloud growth, versus significant concerns over its substantial debt load and capital expenditures, particularly after recent developments around its data center partnerships.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its co-founders establish a new mRNA innovations company and Pfizer reportedly sells its stake, fueling community debate over the company's strategic pivot to its robust oncology pipeline, backed by significant cash reserves, amidst broader market skepticism about mRNA technology.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a substantial Q4 earnings beat, driven by strong MIPLYFFA sales, which has sparked widespread community optimism about the company's shift to profitability and its undervalued status, with many anticipating further upside from upcoming European approval.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is a hot topic after its recent earnings showed a beat on Q4 results but presented a cautious outlook for the coming fiscal year, fueling mixed sentiment. While many in the community are debating short squeeze potential and highlighting the company's substantial real estate assets, others are concerned about soft sales trends and the broader challenging retail landscape.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is gaining traction after the National Oceanic and Atmospheric Administration (NOAA) deemed its extensive deep-seabed mining application in substantial compliance, a critical regulatory step expanding its project footprint. This news is energizing community discussions around a potential permitting race against the International Seabed Authority (ISA) and underscores the growing geopolitical urgency for critical mineral independence.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed following an analyst upgrade highlighting strong demand for its upcoming R2, which is set for a highly anticipated unveiling on March 12. This event is fueling community excitement and debate over its transformative potential and pricing amidst rising oil costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference

Celcuity (NASDAQ:CELC) CEO and co-founder Brian Sullivan outlined the company's clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD...

Vanguard Group Inc. Raises Stock Position in Celcuity, Inc. $CELC

Vanguard Group Inc. grew its stake in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 23.5% in the third quarter, according to the company in its most recent 13F filing with the Securities...

TD Asset Management Inc Invests $3.60 Million in Celcuity, Inc. $CELC

TD Asset Management Inc purchased a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

Artisan Partners Limited Partnership Boosts Stock Holdings in Celcuity, Inc. $CELC

Artisan Partners Limited Partnership lifted its position in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 45.9% in the 3rd quarter, according to the company in its most recent 13F filing with the...

Patient Square Capital LP Acquires Shares of 100,000 Celcuity, Inc. $CELC

Patient Square Capital LP acquired a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

Key PointsPerceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing...

Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat.com reports...

Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?

Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.

Soleus Adds a Significant Number of Celcuity Shares

Key PointsSoleus increased its Celcuity stake by 629,398 shares...

Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference

Celcuity (NASDAQ:CELC) CEO Brian Sullivan outlined the company's expected regulatory timeline and commercial preparations for gedatolisib during an appearance at the Guggenheim Healthcare Conference...

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

CELC
Celcuity Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CELC News

CELCCelcuity Inc